Skip to main content
Home
    • en
    • fr

  • Search form

Main menu

  • About us
    • Our mission
    • Facts & Figures
    • Our Strategy
    • Corporate Governance/ Executive Committee
    • bioMérieux Worldwide
    • Our History
    • Innovation
    • Institut Mérieux

  • Responsibility
    • Our ambition
    • Health
    • Planet
    • Healthcare ecosystem
    • Employees
    • Extended Company
    • SantéRESISTANCE TO ANTIBIOTICS
    • PlanèteCOVID-19 EXCEPTIONAL DONATIONS
  • Solutions
    • Clinical Solutions
    • Industry Solutions
    • Product Quality & Safety
    • Customer Service
    • Cybersecurity
    • Resource Center
    • CLINICAL SOLUTIONS
    • INDUSTRY SOLUTIONS
  • Expertise
    • The importance of diagnostics
      • Clinical diagnostics
      • Industrial Microbiological Control
    • Clinical applications
      • Infectious diseases
      • COVID-19
      • Antimicrobial resistance and Healthcare-associated infections
      • Cardiovascular Emergencies
      • Personalized medicine
    • Industrial applications
      • Agri-food sector
      • Biopharma & cosmetics sectors
    • Our technologies, systems and services
      • Microbiology
      • Molecular Biology
      • Immunoassays
      • Services
    • Glossary of Scientific Terms
  • Education
    • Antimicrobial Resistance / Antimicrobial Stewardship
      • Webinars
      • Educational Materials
      • External Resources
    • Sepsis / Bloodstream Infections
      • Webinars
      • Educational Tutorials
      • Educational Materials
      • External Resources
    • COVID-19
      • Webinars
    • Acute Kidney Injury
      • Webinars & Symposiums
      • Educational Materials
      • External Resources
    • Cardiac Emergencies
      • Educational Tutorials
      • Educational Materials
    • Educational booklets
  • Investors
    • The bioMérieux Share
    • Publications
    • Regulated Information
    • Governance
    • Shareholder area
    • UNIVERSAL REGISTRATION DOCUMENT
    • CORPORATE SOCIAL RESPONSIBILITY
  • Newsroom
    • Press Releases
    • Corporate calendar
    • Media Center
    • About bioMérieux
    • bioMérieux announces the CE marking of the new generation semi-quantitative VIDAS® SARS-COV-2 IgG II serology test
    • PRESS CONTACTS
     
  • Careers
    • Joining bioMérieux
      • Corporate culture
      • Public health mission
      • International presence
      • Professional development
      • Diversity and inclusion
      • Well-being at work
      • Compensation and benefits
    • Job Profiles
      • R&D
      • Manufacturing
      • Supply Chain
      • Information Systems
      • Quality
      • Business
      • Support Functions
      • Medical Affairs
      • HSE
      • Clinical Affairs and Regulatory Affairs
  • Contact us
Home
  • About us
    • Our mission
    • Facts & Figures
    • Our Strategy
    • Corporate Governance/ Executive Committee
    • bioMérieux Worldwide
    • Our History
    • Innovation
    • Institut Mérieux
  • Responsibility
    • Our ambition
    • Health
    • Planet
    • Healthcare ecosystem
    • Employees
    • Extended Company
  • Solutions
    • Clinical Solutions
    • Industry Solutions
    • Product Quality & Safety
    • Customer Service
    • Cybersecurity
    • Resource Center
  • Expertise
    • The importance of diagnostics
    • Clinical applications
    • Industrial applications
    • Our technologies, systems and services
    • Glossary of Scientific Terms
  • Education
    • Antimicrobial Resistance / Antimicrobial Stewardship
    • Sepsis / Bloodstream Infections
    • COVID-19
    • Acute Kidney Injury
    • Cardiac Emergencies
    • Educational booklets
  • Investors
    • The bioMérieux Share
    • Publications
    • Regulated Information
    • Governance
    • Shareholder area
  • Newsroom
    • Press Releases
    • Corporate calendar
    • Media Center
    • About bioMérieux
  • Careers
    • Joining bioMérieux
    • Job Profiles
  • Contact us
    • Investor Relations
    • Press Contacts
    • en
    • fr

  • Search form

You are here

Printer-friendly version
  • Home
  • Responsibility
  • Healthcare ecosystem
  • Personal information and privacy
  • Information notice for CSR
Responsibility
  • Our ambition
  • Health
    • Resistance to antibiotics
    • Fight against sepsis
  • Planet
    • Product life cycle
    • Supply and distribution
  • Healthcare ecosystem
    • Patient Relationship
    • Public and Government Affairs
    • Global Code of Conduct
    • Expressing concerns
    • Preventing corruption
    • Relationships with Third Parties
    • Personal information and privacy
      • bioMérieux's GDPR Statement
      • Rights of the data subjects
      • Information notice for customers and prospects
      • Information notice for investigators
      • Information notice for suppliers
      • Information notice for distributors
      • Information notice for CSR
      • Data processors’ list
  • Employees
    • Safety at work
    • Professional development and well-being at work
    • Diversity and inclusion
    • Our employees' success
    • The importance of social dialogue
  • Extended Company
    • Sustainable and socially inclusive purchasing
    • Acting against epidemics
    • Philanthropy
      • COVID-19 Exceptional Donations
      • Strong ties with academic institutions
      • Strong ties with associative actors
    • Promoting access to diagnostics

Information notice for CSR 

Press Release
  • May 07, 2021 bioMérieux announces the CE marking of the new generation semi-qua...
  • April 30, 2021 bioMérieux announces CE-marking of the new MALDI-TOF mass spectrom...
  • April 27, 2021 bioMérieux – First-Quarter 2021 Business Review
  • April 07, 2021 bioMérieux announces the CE marking of 3 dengue immunoassays on VI...
Annual Report

Clinical Solutions

To discover all of our products for Clinical applications, please visit bioMérieux Diagnostics website.

Industry Solutions

To discover all of our products for industrial microbiological control, please visit our bioMérieux Industry website.

 

Read the document

Pioneering diagnostics
  • Legal Notice
  • Privacy
  • Cookie Policy
  • Contact
  • Copyright 2020 bioMérieux SA
  • biomerieux.com
  • bioMérieux Worldwide >
    Discover all our locations
    Asia
    • China (Website)
    • India (Website)
    • Indonesia (website)
    • Japan (Website)
    • Korea
    • Malaysia (website)
    • Philippines (website)
    • Singapore (Website)
    • Thailand (website)
    • Vietnam (website)
    Europe, Middle East, Africa
    • Algeria
    • Austria (Website)
    • Belgium
    • Czech Republic (Website)
    • Denmark (Website)
    • Finland (Website)
    • France (Website)
    • Germany (Website)
    • Greece
    • Hungary (Website)
    • Italy (Website)
    • Ivory Coast
    • Netherlands
    • Norway (Website)
    • Poland (Website)
    • Portugal (Website)
    • Russia (Website)
    • Serbia
    • South Africa (Website)
    • Spain (Website)
    • Sweden (Website)
    • Switzerland (Website)
    • Turkey (Website)
    • United Arab Emirates
    • United Kingdom (Website)
    North America
    • Canada (Website)
    • United States (Website)
    Oceania
    • Australia (Website)
    • New Zealand (Website)
    South America
    • Argentina (Website)
    • Brazil (Website)
    • Chile (Website)
    • Colombia (Website)
    • Mexico (Website)
  • Our Specific Websites >
    • Antimicrobial Resistance Website
    • BioFire Diagnostics
    • bioMérieux Clinical Diagnostics
    • bioMérieux Industry
    • bioMérieux Investors
    • bioMérieux Recruitment
    • bioMérieux Culture Media
  • Our communities >
    • mybiomerieux.com